|
|
|
| First Name: | Philippe | | Last Name: | Marambaud | | Title: | Associate Investigator | | Advanced Degrees: | Ph.D. | | Affiliation: | The Feinstein Institute for Medical Research - North-Shore LIJ | | Department: | Litwin-Zucker Research Center | | Street Address 1: | 350 Community Drive | | City: | Manhasset | | State/Province: | NY | | Zip/Postal Code: | 11030 | Country/Territory: | U.S.A. | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports no financial or other potential conflicts of interest. [Last Modified: 19 March 2013]
|
|
|
View all comments by Philippe Marambaud
|
Aging Process, Parkinson Disease, Prion Diseases, Tauopathies, Polyglutamine Disorders (Huntington's, etc.), Alzheimer Disease
|
Tau/Cytoskeleton, Neurotransmission, Genetics, A-beta PP/A-beta, Molecular and Cell biology, Signal transduction, Animal Models, Neurobiology
|
1. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK. “A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions.” EMBO J 2002; 21(8):1948-56.
2. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK. “A CBP-binding transcriptional repressor produced by the PS1/gamma-cleavage of N-cadherin is inhibited by PS1 FAD mutations.” Cell 2003; 114, 635-645.
3. Marambaud P, Zhao H, Davies P. “Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides.” J Biol Chem 2005, 280: 37377-82.
4. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P. “A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer’s disease risk.” Cell 2008; 133(7):1149-61.
5. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P. “AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.” J Biol Chem 2010;285(12):9100-13.
6. Vingtdeux V, Davies P, Dickson DW, Marambaud P. “AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies.” Acta Neuropathol 2011; 121(3):337-49.
7. Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Hampel H, Gordon ML, Christen E, Chapuis J, Greenwald BS, Davies P, Marambaud P. “CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer’s disease.” Mol Med 2011; 17(9-10):974-9.
8. Ma Z, Siebert AP, Cheung KH, Lee RJ, Johnson B, Cohen AS, Vingtdeux V, Marambaud P, Foskett JK. “Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca2+ regulation of neuronal excitability.” PNAS 2012 Jul 10; 109(28): E1963-71.
9. Dreses-Werringloer U, Vingtdeux V, Zhao H, Chandakkar P, Davies P, Marambaud P. “CALHM1 controls Ca2+-dependent MEK/ERK/RSK/MSK signaling in neurons.” J Cell Sci 2013; in press.
10. Taruno A, Vingtdeux V, Ohmoto M, Ma Z, Dvoryanchikov G, Li A, Adrien L, Zhao H, Leung S, Abernethy M, Koppel K, Davies P, Civan M, Chaudhari N, Matsumoto H, Hellekant G, Tordoff M, Marambaud P#, Foskett JK# (#co-senior/co-corresponding authors). “CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes.” Nature 2013 Mar 14;495(7440):223-6. |
|
|